AI assistant
TherapeuticsMD, Inc. — Director's Dealing 2020
Aug 8, 2020
35134_dirs_2020-08-07_dfe8ed7b-9b34-4f0f-a170-d1485ac7ffcf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2020-08-01
Reporting Person: Walker Marlan D (General Counsel)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) | $2.98 | 2023-06-21 | Common Stock (80000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $2.98 | 2023-06-21 | Common Stock (100000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $3.14 | 2023-10-03 | Common Stock (15000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $4.02 | 2024-06-05 | Common Stock (100000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $4.02 | 2024-06-05 | Common Stock (195000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $4.01 | 2024-11-21 | Common Stock (100000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $7.72 | 2025-06-04 | Common Stock (100000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $6.26 | 2026-09-22 | Common Stock (150000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $6.83 | 2027-03-15 | Common Stock (25000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $5.16 | 2028-03-15 | Common Stock (120000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $2.18 | 2029-07-30 | Common Stock (200000) | Direct | |
| Restricted Stock Units | $0 | Common Stock (230000) | Direct | ||
| Restricted Stock Units | $0 | Common Stock (151500) | Direct | ||
| Performance Stock Units | $0 | Common Stock (151500) | Direct |
Footnotes
F1: Underlying shares vested as follows: (i) 26,667 shares on June 21, 2014, (ii) 26,666 shares on June 21, 2015 and (iii) 26,667 shares on June 21, 2016.
F2: Underlying shares each vested on December 21, 2014.
F3: Underlying shares vested in four equal installments annually, becoming fully vested on October 3, 2017.
F4: Underlying shares each vested on June 5, 2015.
F5: Underlying shares each vested on June 5, 2014.
F6: Underlying shares each vested on November 21, 2014.
F7: Underlying shares vested in two equal installments annually, becoming fully vested on June 4, 2017.
F8: Underlying shares vested in three equal installments annually, becoming fully vested on September 22, 2019.
F9: Underlying shares vest in four equal installments annually, becoming fully vested on March 15, 2021.
F10: Underlying shares vest in three equal installments annually, becoming fully vested on March 15, 2021.
F11: Underlying shares vest in four equal installments annually, becoming fully vested on July 30, 2023.
F12: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on December 13, 2021.
F13: Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in three equal installments annually, becoming fully vested on March 30, 2023.
F14: The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.